Travere Therapeutics (TVTX) Other financing activities (2014 - 2026)

Travere Therapeutics' Other financing activities history runs 13 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• Quarterly Other financing activities rose 11.45% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.2 million (up 730.33% YoY) and the FY2025 annual result came in at $34.7 million, changed N/A from the prior year.
• Other financing activities was $4.7 million for Q1 2026 at Travere Therapeutics, down from $25.9 million in the prior quarter.
• Across five years, Other financing activities topped out at $25.9 million in Q4 2025 and bottomed at -$4.2 million in Q3 2023.
• A 5-year average of $2.7 million and a median of $1.3 million in 2024 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 4644.48% in 2025, while the deepest fall reached 307.04% in 2025.
• Travere Therapeutics' Other financing activities stood at -$4.0 million in 2022, then jumped by 207.01% to $4.3 million in 2023, then sank by 113.31% to -$571000.0 in 2024, then surged by 4644.48% to $25.9 million in 2025, then sank by 81.78% to $4.7 million in 2026.
• Business Quant data shows TVTX's Other financing activities at $4.7 million in Q1 2026, $25.9 million in Q4 2025, and $7.3 million in Q3 2025.